The recommendations listed in this guideline are, whenever possible, evidence based. An
initial extensive evidence review, which included literature derived from research involving …

Aim This executive summary of the hypertrophic cardiomyopathy clinical practice guideline
provides recommendations and algorithms for clinicians to diagnose and manage …

Implantable cardioverter-defibrillator (ICD) therapy is clearly an effective therapy for selected
patients in definable populations. The benefits and risks of ICD therapy are directly impacted …

Guidelines Liaison; cHFSA Representative; dASE Representative; eHRS Representative;
fSCMR Representative; gAATS Representative; hSCAI Representative; and iFormer Joint …

Abstract Aim The “2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the
Management of Hypertrophic Cardiomyopathy” provides recommendations to guide …

Abstract Aims Single-chamber (VR-ICD) and subcutaneous (S-ICD) implantable cardioverter-
defibrillators are effective to protect patients against sudden death but expose them to higher …

Abstract Aims Implantable cardioverter defibrillators (ICDs) are an effective primary
prevention of sudden cardiac death. We examined whether dual-chamber (DC) ICDs confer …

Background The absence of pacing capabilities may reduce the appeal of subcutaneous
implantable cardioverter-defibrillator (S-ICD) devices for patients at risk for conduction …

Introduction Subclinical atrial fibrillation (AF), in the form of cardiac implantable device‐
detected atrial high rate episodes (AHREs), has been associated with increased …

Abstract Aims Implantable cardioverter-defibrillators (ICDs) are key in the prevention of
sudden cardiac death, but outcomes may vary by type of device or programming [single …